Elizabeth Mann, Managing Partner California’s legislature passed a law that required PE firms and hedge funds to obtain prior written consent from the AG’s office before closing a transaction that involved a material investment in, or a change of control of, a California healthcare facility or provider group. Governor Newsom vetoed this bill.  His rationale […]

Elizabeth Mann, Managing Partner California’s legislature passed Assembly Bill 3129 on August 31, 2024. Governor Newsom has 30 days to veto or sign the new law.  If signed, the statute becomes effective on January 1, 2025.This law would significantly increase the California Attorney General’s powers to review and, in some circumstances, prevent private equity groups […]

CMS recently adopted new rules that regulate the amount that Medicare Advantage and MAPD plans can pay to third parties for providing administrative services. These services include providing Health Benefit Assessment support and call center services, developing software to permit agents to compare plan benefits, helping beneficiaries fill out forms and monitoring agent licensure and […]

  The California legislature is debating proposed legislation (Assembly Bill 3129) that would significantly increase the California Attorney General’s powers to review and, in some circumstances, prevent private equity groups and hedge funds from investing in California hospitals, physician practices and the like. In order to become law, AB 3129 must secure approval in both […]

Of the many Pandemic-era novelties—including mask mandates, work from home, and the resurgence of outdoor dining—perhaps none is more pronounced in Southern California than the proliferation of electric bicycles (“e-bikes”). From the streets to the Strand, they are seemingly everywhere. In 2020 alone, Manhattan Beach saw e-bike sales soar more than 900%. Unfortunately, this meteoric […]

  CHANGES COMING TO THE INSULIN MARKET! Branded as “$30 Insulin by CalRx,” Governor Newsom announced on March 18, 2023, that California has entered into a $50 million, ten-year contract with Civica Rx for it to manufacture and distribute generic insulin in California. While Civica still needs to obtain FDA approval for its proposed insulin […]

In a groundbreaking report, the Insurance Research Counsel (“IRC”) reported that litigation against property owners—including hotels, retail buildings, senior living facilities and corporate headquarters—is increasing in intensity and cost throughout the United States. The IRC attributes this to what it describes as “social inflation,” which includes the breakdown of societal inhibitions against filing lawsuits, the […]

  Every two years, California paralegals are required to complete Mandatory Continuing Legal Education (MCLE) requirements.  These MCLE requirements must consist of four hours of education in legal ethics and four hours of either general law or an area of specialized law.  A simple online search will return hundreds of companies that offer courses to […]

Introduction to Defamation Law in California California defines defamation as a false statement of fact, knowingly made by the defendant to a third party, that causes the plaintiff to suffer damages.[i] Slander and libel are two forms of defamation; slander is spoken, libel is written. Where the plaintiff is a private citizen, and the defamatory […]

California’s 2022 – 2023 budget allocates slightly more than $100 million to establish the CalRx Biosimilar Initiative – where California will develop, in partnership with a contract manufacturer, biosimilar insulin products and sell them at very reasonable prices. California intends to be selling insulin products, at a massive scale, within a few short years. 37 […]